| 763818 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome |
2021-11-01 |
10.1136/jitc-2021-sitc2021.024 |
Mallardo Domenico, Vitale Maria Grazia, Giannarelli Diana, Trillò Giusy, Esposito Assunta, Capone Mariaelena, Isgrò Maria Antonietta, Madonna Gabriele, D’Angelo Grazia, Festino Lucia, Vanella Vito, Trojaniello Claudia, Manzoni Alessandro, White Andrew, Bailey Michael, Simeone Ester, Caracò Corrado, Maiolino Piera, Normanno Nicola, Warren Sarah, Cavalcanti Ernesta, Ascierto Paolo |
| 763817 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
90 Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers |
2021-11-01 |
10.1136/jitc-2021-sitc2021.090 |
Beeler Kristina, Bruderer Roland, Tognetti Marco, Sklodowski Kamil, Mueller Sebastian, Kamber Dominique, Reiter Lukas |
| 763816 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.444 |
Felices Martin, Warlick Erica, Juckett Mark, Weisdorf Daniel, Vallera Daniel, Miller Sarah, Wangen Rose, Lewis Dixie, Knox JoAnne, Schroeder Martin, Miller Jeffrey |
| 763815 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.525 |
Symeonides Stefan, Mahalingam Devalingam, Chae Young Kwang, Calvo Emiliano, Miguel Maria, Arkenau Hendrik-Tobias, Garralda Elena, Galvao Vladimir, Mita Alain, Hassan Hariz, Baumhauer Annette, Völker Timo, Kühnle Marie-Cristine, Rösemann Roman, Strobl Stefan, Tuereci Oezlem, Sahin Ugur |
| 763814 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.023 |
Perez Diego de Miguel, Barrón Feliciano, Russo Alessandro, Lara-Mejía Luis, Gunasekaran Muthukumar, Cardona Andrés, Peterson Christine, Colen Rivka, Naing Aung, Mack Philip, Hirsch Fred, Adamo Vincenzo, Arrieta Oscar, Rolfo Christian |
| 763813 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.017 |
Raza Afsheen, Mohsen Reyad, Kanbour Aladdin, Zar Gul Abdul Rehman, Philip Anite, Vijayakumar Suma, Hydrose Shereena, Merhi Maysaloun, Inchakalody Varghese, Uddin Shahab, Homsi Mohammed Ussama Al, Dermime Said |
| 763812 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.448 |
Stadtmauer Edward, Karlin Lionel, Weisel Katja, Gatt Moshe Etzion, Kansagra Ankit, Monohan Gregory, Yee Andrew, Rockow-Magnone Shayna, Cordero Jose, Hoffman David, Bueno Orlando, Wu Kevin, Gasparetto Cristina |
| 763811 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
372 Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab |
2021-11-01 |
10.1136/jitc-2021-sitc2021.372 |
Shen Lin, Zhang Qingyuan, Liu Tianshu, Pan Hongming, Bai Yuxian, Yuan Ying, Luo Xuerui, Shi Yang, Zhang Yun, Huang Ruiqi, Zhang Juan, Shen Zhirong |
| 763810 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
262 Preclinical characterization of humanized anti-siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression |
2021-11-01 |
10.1136/jitc-2021-sitc2021.262 |
Dinh Huyen, Lam Sam, Wall Valerie, Zapata Francisco, Whitman Darbie, Chandrasekaran Ramya, Loh Lauren, Loh Texia, Graddis Tom, Probst Peter, Bouchlaka Myriam |
| 763809 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
336 Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.336 |
Piccioni David, Piccioni David, Bota Daniela, LaRocca Renato, Kesari Santosh, Carillo Jose, Kong Xiao-Tang, Duma Christopher, Abedi Mehrdad, Aiken Robert, Taylor Thomas, Hsieh Candace, Nistor Gabriel, Dillman Robert |
